Markets:

Overview

News

Currencies

International

Treasuries

Legacy Reserves Inc. - Common Stock (NY:LGCY)

9.960 -0.570 (-5.41%)

Official Closing Price Updated: 4:10 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Legacy Reserves Inc. - Common Stock

Legacy Education Inc (NYSEARCA:LGCY) Reports Q1 2026 Revenue Beat Driven by Enrollment Growth ↗

November 13, 2025

Legacy Education (LGCY) Q1 2026 earnings beat revenue estimates with strong growth driven by a surge in student enrollment.

Via Chartmill

Topics Earnings

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

A Preview Of Legacy Education's Earnings ↗

November 12, 2025

Via Benzinga

Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

September 26, 2025

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Friday.

Via Benzinga

Topics Stocks

Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket ↗

September 26, 2025

Shares of Top KingWin Ltd (NASDAQ: WAI) rose sharply in pre-market trading after the company announced it entered into a sales contract with Walker Times International for the sale of 10,000 units of...

Via Benzinga

Topics Artificial Intelligence

Earnings Preview For Legacy Education ↗

September 24, 2025

Via Benzinga

Earnings Scheduled For February 13, 2025 ↗

February 13, 2025

Via Benzinga

4 Analysts Have This To Say About Legacy Education ↗

December 20, 2024

Via Benzinga

Legacy Education Inc (NYSEARCA:LGCY) Stock Falls After Q4 Earnings Miss ↗

September 25, 2025

Legacy Education (LGCY) reported Q4 revenue beat but a significant EPS miss, causing the stock to drop nearly 10%. Full-year revenue grew 40%, yet the earnings miss overshadowed the strong growth.

Via Chartmill

Topics Earnings

Earnings Scheduled For September 25, 2025 ↗

September 25, 2025

Companies Reporting Before The Bell • Accenture (NYSE: ACN) is likely to report quarterly earnings at $2.97 per share on revenue of $17.34 billion.

Via Benzinga

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session ↗

August 26, 2025

Via Benzinga

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session ↗

July 22, 2025

Via Benzinga

10 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session ↗

June 24, 2025

Via Benzinga

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session ↗

May 16, 2025

Via Benzinga

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session ↗

May 07, 2025

Via Benzinga

Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

April 17, 2025

Via Benzinga

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

No Fear And No Panic After A 10% Correction = No Bottom ↗

March 28, 2025

In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.

Via Talk Markets

Topics Stocks / Equities

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session ↗

February 14, 2025

Via Benzinga

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session ↗

January 15, 2025

Via Benzinga

12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session ↗

November 15, 2024

Via Benzinga

Self-Driving Startup Pony.ai Files For U.S. IPO ↗

October 20, 2024

Self-driving startup Pony.ai of China filed for an IPO in the U.S. this week. Meanwhile, four companies -- Springview Holdings, Oriental Rise Holdings, PTL Limited, and Samfine Creation Holdings Group...

Via Talk Markets

Topics Initial Public Offering

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session ↗

October 08, 2024

Via Benzinga

Obesity Drug Developer BioAge Makes Nasdaq Debut ↗

September 29, 2024

Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead obesity drug further into clinical trials.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.